Payment overview · 2025
General Payments
$654.53
36 reported records · 14 companies
Healthcare provider profile · identity verified
Raazia Aftab, MD
Allopathic & Osteopathic Physicians|Internal Medicine · URBANA, IL · NPI 1629554696
Verified facts
What the public records show
CMS Open Payments records show Raazia Aftab, MD received $654.53 in general payments during 2025 across 36 reported records.
Lilly USA, LLC accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.36 | 18.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.84 | 11.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $62.90 | 9.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.49 | 9.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.64 | 7.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.01 | 7.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.66 | 6.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.25 | 6.8% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $30.62 | 4.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.48 | 4.7% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $27.61 | 4.2% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.47 | 3.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.30 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.90 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $654.53 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.65 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $62.90 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.64 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.66 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.25 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.61 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $27.61 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 578 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 119 |
| Losartan Potassium | Losartan Potassium | 415 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 404 | 105 |
| Lisinopril | Lisinopril | 368 | 100 |
| Omeprazole | Omeprazole | 284 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 72 |
| Gabapentin | Gabapentin | 234 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 50 |
| Alendronate Sodium | Alendronate Sodium | 222 | 52 |
| Simvastatin | Simvastatin | 218 | 59 |
| Metformin Hcl Er | Metformin Hcl | 185 | 52 |
| Furosemide | Furosemide | 182 | 46 |
| Potassium Chloride | Potassium Chloride | 174 | 51 |
| Trazodone Hcl | Trazodone Hcl | 156 | 45 |
| Carvedilol | Carvedilol | 136 | 34 |
| Buspirone Hcl | Buspirone Hcl | 134 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 38 |
| Metformin Hcl | Metformin Hcl | 119 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 38 |
| Montelukast Sodium | Montelukast Sodium | 115 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 42 |
| Sertraline Hcl | Sertraline Hcl | 110 | 29 |
| Bupropion Xl | Bupropion Hcl | 109 | 24 |
| Meloxicam | Meloxicam | 109 | 33 |
| Allopurinol | Allopurinol | 108 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 32 |
| Ezetimibe | Ezetimibe | 100 | 31 |
| Famotidine | Famotidine | 100 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 20 |
| Tramadol Hcl | Tramadol Hcl | 75 | 30 |
| Donepezil Hcl | Donepezil Hcl | 73 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 21 |
| Celecoxib | Celecoxib | 72 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 24 |
| Memantine Hcl | Memantine Hcl | 68 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 19 |
| Alprazolam | Alprazolam | 67 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 17 |
| Glimepiride | Glimepiride | 59 | 16 |
| Ozempic | Semaglutide | 59 | 15 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Pregabalin | Pregabalin | 58 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 19 |
| Propranolol Hcl | Propranolol Hcl | 54 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Finasteride | Finasteride | 48 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | suppressed |
| Atenolol | Atenolol | 43 | 13 |
| Jardiance | Empagliflozin | 43 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Diazepam | Diazepam | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 13 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Prednisone | Prednisone | 33 | 26 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 15 |
| Lorazepam | Lorazepam | 32 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 26 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 15 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $654.53 · 36 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, SMARTVEST, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error